Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag 2seventy-bio

PharmaShots Weekly Snapshots (February 13 - 17, 2023)

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA

FDA Vaccines

CHMP backs J&J’s myeloma CAR-T therapy Carvykti

pharmaphorum

MARCH 27, 2022

The decision comes less than a month after Carvykti was approved by the FDA as a fifth-line therapy for multiple myeloma, teeing up a tussle in the market with Bristol-Myers Squibb and bluebird bio spinout 2seventy’s Abecma (idecabtagene autoleucel) which was approved for a similar indication last year.

Labelling

Labelling Immunization FDA

PharmaShots Weekly Snapshots (February 13 - 17, 2023)

CHMP backs J&J’s myeloma CAR-T therapy Carvykti

Stay Connected